Zymeworks price to sales ratio ZYME
Market value divided by revenue over the last twelve months, since 2023.
- Today, Nov 2, 2026
- 55.4×
- 3-year median
- 12.6×
- Against its 3-year history
- 99th
- percentile: 0 is its lowest day, 100 its highest
- 3-year range
- 1.0× to 55.8×
- Peer median
- 1.8×
Zymeworks' price to sales ratio is 55.4× as of Nov 2, 2026.
That is above its 3-year median of 12.6×, higher than on 99% of days in the last 3 years.
Over that time it ranged from 1.0× in Sep 2023 to 55.8× in Sep 2026.
The median for 10 large drugmakers of a similar size is 1.8×.
Price to sales ratio over time
Year by year
| Year | End of year | Low | High |
|---|---|---|---|
| 2026 so far | 55.4× | 12.5× | 55.8× |
| 2025 | 15.0× | 7.4× | 16.6× |
| 2024 | 16.1× | 1.5× | 18.4× |
| 2023 | 1.6× | 1.0× | 1.6× |
Against its peers
Companies in Drug Manufacturers - General nearest Zymeworks' size, closest first, today.
| Company | Price to sales ratio |
|---|---|
| ZYMEZymeworks | 55.4× |
| HRMYHarmony Biosciences | 2.3× |
| PBHPrestige Consumer Healthcare | 2.1× |
| ANIPANI Pharmaceuticals | 1.7× |
| PAHCPhibro Animal Health | 1.0× |
| NRIXNurix Therapeutics | 4.0× |
| PCRXPacira BioSciences | 1.9× |
| ANABAnaptysbio | n/m |
| OMEROmeros | n/m |
| OGNOrganon | 0.6× |
| AMPHAmphastar Pharmaceuticals | 1.6× |
| Peer median | 1.8× |
What the price to sales ratio tells you
Market value divided by revenue over the last twelve months. Useful for companies with little or no profit yet, since sales are harder to make negative than earnings.
Ignores margins entirely. A software company at 10× sales with 30% margins can be cheaper than a grocer at 1× sales with 2% margins.
More on Zymeworks
Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.